The Human Variable 

Stage Zero™ defines the preclinical phase where immune and autonomic instability is already active but not yet captured by traditional diagnostics. By identifying structured symptom patterns, timing-based responses, and multi-system disruption, this framework enables earlier recognition of disease activity across conditions such as Long COVID, ME/CFS, POTS, and autoimmune disorders. Rather than waiting for diagnostic thresholds, Stage Zero™ introduces a trajectory-based model

Why does IBD take months or years to diagnose? The failure is not missing symptoms. It is missing the pattern. CDF-IBD™ introduces a new framework for early detection of inflammatory bowel disease using pattern recognition, flare intelligence, and system-level correction. Designed to address IBS misdiagnosis, referral delays, and fragmented care, this model identifies IBD earlier, improves escalation, and reduces preventable disease progression.

POTS clinical trials often fail by treating a multi-system disorder as a narrow cardiovascular condition. This CYNAERA framework outlines stabilization, phenotype stratification, adaptive design, and real-world endpoints to improve outcomes and reduce trial failure.

Personalized CRISPR Remission™ for Long COVID introduces a state-dependent gene editing framework based on biological readiness, stabilization, and recovery to improve timing, safety, and durability in immune-volatile disease.

Why rheumatoid arthritis is often misdiagnosed or delayed. Learn early RA symptoms, diagnostic gaps, and how CDF-RA™ improves early detection.

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.